The website of the Clinical Services Journal

Some antivirals used in non-severe COVID-19 may reduce hospitalisations and deaths

The antiviral drugs molnupiravir and nirmatrelvir–ritonavir (Paxlovid), when used to treat non-severe COVID-19, most likely reduce the risk of subsequent progression to hospitalisation and death, according to new research published in CMAJ (Canadian Medical Association Journal).

As most trials have focused on patients with severe or critical COVID-19, researchers conducted a systematic review and meta-analysis to understand the effectiveness of these drugs in treating non-severe COVID-19.

The researchers identified 41 trials involving 18 568 patients with non-severe COVID-19, most of whom were aged 36.5 to 65.5 years. Compared with standard care or placebo, nirmatrelvir–ritonavir likely reduced the risk of hospital admission (46.2 fewer admissions per 1000), and molnupiravir probably reduced the risk (16.3 fewer admissions per 1000).

These findings have implications for healthcare systems and clinical guidelines.

"Our findings suggest that nirmatrelvir–ritonavir may be superior to molnupiravir for some outcomes, which has implications for organizations, such as the [World Health Organization] WHO, that are in the process of developing recommendations addressing molnupiravir and nirmatrelvir–ritonavir," the authors wrote. "Healthcare systems deciding on drug procurement and cost issues need to consider the relative efficacy of nirmatrelvir–ritonavir over molnupiravir."

In a related commentary, the authors pointed out there are challenges in applying these findings to current patients with COVID-19. Several of the trials on which the study is based were conducted among unvaccinated patients who had been infected with the Delta variant. As a significant portion of the population is now vaccinated and many have been infected with the Omicron variant, the medications may be less effective in a real-world setting.

"As the virus and population dynamics evolve, ongoing research is required to inform clinical and policy decisions," wrote Drs. Corinne Hohl, University of British Columbia and Vancouver Coastal Health Research Institute, Vancouver, BC, and Andrew McRae, University of Calgary, Calgary, Alberta. "Adaptive platform trials and large observational studies offer the best opportunities to generate timely evidence on the effectiveness of COVID-19 therapeutics."

Visit: https://www.cmaj.ca/lookup/doi/10.1503/cmaj.220471

Upcoming Events

AfPP Annual Conference 2022

University of York
8-11 September 2022

Infection 360: What's trending in infection prevention & control

Edgbaston Stadium, Birmingham
27-28 September 2022

IP2022 IS COMING TO BOURNEMOUTH IN OCTOBER 2022

Bournemouth
17-19 October 2022

UKHCA Conference: Listen Up

Pendulum Hotel and Manchester Conference Centre, Manchester
3rd November 2022

MEDICA 2022

Dusseldorf Germany
14th November - 17th November

Future Surgery 2022

ExCel, London
15th - 16th November 2022

Access the latest issue of Clinical Services Journal on your mobile device together with an archive of back issues.

Download the FREE Clinical Services Journal app from your device's App store

Upcoming Events

AfPP Annual Conference 2022

University of York
8-11 September 2022

Infection 360: What's trending in infection prevention & control

Edgbaston Stadium, Birmingham
27-28 September 2022

IP2022 IS COMING TO BOURNEMOUTH IN OCTOBER 2022

Bournemouth
17-19 October 2022

UKHCA Conference: Listen Up

Pendulum Hotel and Manchester Conference Centre, Manchester
3rd November 2022

MEDICA 2022

Dusseldorf Germany
14th November - 17th November

Future Surgery 2022

ExCel, London
15th - 16th November 2022

Access the latest issue of Clinical Services Journal on your mobile device together with an archive of back issues.

Download the FREE Clinical Services Journal app from your device's App store

Step Communications Ltd, Step House, North Farm Road, Tunbridge Wells, Kent TN2 3DR
Tel: 01892 779999 Fax: 01892 616177
www.step-communications.com
© 2022 Step Communications Ltd. Registered in England. Registration Number 3893025